Traders should monitor for topline 6-month data in early Q4 2026, which could be a significant catalyst. The late Q4 2026 potential FDA submission timeline depends on De Novo pathway feedback in Q2 2026. The reaffirmed cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
Fractyl Health announced completion of participant randomization in its REMAIN-1 Pivotal Cohort study evaluating Revita for weight maintenance after GLP-1 therapy discontinuation. The company expects topline 6-month data in early Q4 2026 and a potential FDA marketing application submission in late Q4 2026, while reaffirming its cash runway into early 2027.
Key Facts
- Completed participant randomization in the REMAIN-1 Pivotal Cohort study for Revita, a device for post-GLP-1 weight maintenance
- Topline 6-month pivotal data expected in early Q4 2026
- Potential FDA marketing application submission anticipated in late Q4 2026, contingent on De Novo pathway feedback expected in Q2 2026
- Company reiterated cash runway guidance into early 2027
- Co-primary endpoints: percent total body weight regain at 6 months and proportion maintaining ≥5% weight loss at 12 months
Financial Impact
No immediate financial impact; reaffirmed cash runway into early 2027 supports operations through pivotal data readout
Risk Factors
- Clinical trial results may not meet co-primary endpoints
- FDA may not accept De Novo pathway for Revita, delaying regulatory submission
- Competitive landscape in obesity treatments is rapidly evolving with pharmaceutical GLP-1 agents
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073374 |
| Document: guts-ex99_1.htm | 0001193125-26-073374 |
| Document: 0001193125-26-073374-index-headers.html | 0001193125-26-073374 |
| Document: 0001193125-26-073374-index.html | 0001193125-26-073374 |
| Document: 0001193125-26-073374.txt | 0001193125-26-073374 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $1.13 | awaiting T+5 | — | $1.08 (−4.42%) |
Oct 16, 2026 10d ago | 8-K | $1.55 $1.08 | ▼ −30.32% | ▼ −30.42% | $1.08 (−30.32%) |
Oct 13, 2026 12d ago | SC 13G | $4.03 $1.33 | ▼ −66.96% | ▼ −65.80% | $1.08 (−73.17%) |
Aug 10, 2026 10w ago | 8-K | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Aug 10, 2026 10w ago | Press Release | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Jul 15, 2026 14w ago | 8-K | $0.9100 $0.7580 | ▼ −16.70% | ▼ −15.72% | $1.08 (+18.68%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Insider Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.7239 $0.8500 | ▲ +17.42% | ▲ +16.99% | $1.08 (+49.19%) |
Jun 4, 2026 20w ago | 8-K | $0.7340 $0.7240 | ▼ −1.36% | ▲ +1.19% | $1.08 (+47.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers